Global Perfusion Systems Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Component, Type, Technique & Region - Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 3409
Pages: 175

Perfusion Systems Market Size (2024 to 2029)

The global perfusion systems market was valued at USD 1.20 billion in 2024. It is estimated to grow at a CAGR of 3.4% and be worth USD 1.42 billion by 2029.

Current Scenario Of The Perfusion Systems Market

Perfusion systems provide the energy needed to overcome resistance to blood flow through perfusion pressure. The resistances can be associated with vessel diameter, viscosity, red blood cell deformability, capillary lumen obstructions, and hydrodynamic effects at vessel bifurcations. Here, a specific area of the body receives large doses of drugs called regional infusion to bathe an organ or tissue composed of the tubing, the pump, the plasma or blood vessels, the heart, and blood. Bypass cardiopulmonary systems use perfusion systems to surgically treat patients with cardiac and respiratory diseases. Heart-lung machines supply oxygen and remove carbon dioxide in patients when the heart and lungs fail to carry out the process of blood oxygenation. Organ perfusion systems deliver extracorporeal circulation to the patient's organs.


YOY growth in the prevalence of cardiovascular diseases and respiratory diseases across the world, YOY growth in the aging population, and rising biologics manufacturing activities are propelling the global perfusion systems market growth.

According to the World Health Organization (WHO) reports, it is estimated that every year, an estimated 17.9 million people die globally due to CVDs, popularly heart attacks and strokes. Furthermore, in 2013, it was estimated that over 1 billion people suffered from hypertension, 40% globally. Some of the essential advantages of perfusion systems are their ability to increase plant capacity, throughput, and productivity, become an alternative manufacturing strategy, increase renewed interest in infusion technology with a reduced scale of operation and reduced cost, and use tangential flow filtration to solve historical challenges. Furthermore, since it allows uniform and flexible cell culture perfusion, the non-optimized perfusion process achieves higher cell density and higher viability up to 10 times for higher cell growth rates, higher productivity, and healthier cultures; this technique is more commonly being used, leading to its more adoption, thereby driving the growth of perfusion systems market.

An increase in multiple organ failures and an increasing number of lung diseases in developed and emerging nations are further expected to accelerate market growth.

Moreover, the government's and NGOs' initiatives to encourage organ donations and increase investments by the government and NGOs to improve research activities and healthcare infrastructure facilities are projected to escalate the global perfusion systems market growth. In the case of perfusion cultures, an award-winning technology, XCell ATF, minimizes cellular shearing while maintaining cells in culture and keeps cells in constant equilibrium with the contents of the bioreactor, helping cell growth at higher densities, becoming the primary infusion device for the production of mAb and protein. In addition, this helps prevent filtering worries since it automatically switches to a second hollow fiber filter without requiring a backup system.


High costs associated with organ transplantations and ethical concerns regarding stem cell therapy research activities are restraining the global perfusion systems market growth.

One of the main limitations of perfusion cultures is the failure of these systems, though rarely, leading to many other consequences primarily due to space limitations. A sufficient number of well-trained surgeons in emerging nations and low-cost products hamper the market growth. In addition, low perfusion causes numerous health problems, such as coronary artery diseases, which is also a challenging market growth factor.

Impact Of COVID-19 On The Global Perfusion Systems Market

COVID-19 was declared a pandemic by World Health Organization. COVID-19 had negatively impacted the perfusion systems market growth during the first half of COVID-19. Due to lockdown restrictions worldwide, the market experienced a growth rate during the pandemic. However, the latter period significantly impacted the market growth as several organ transplantations were made, which were postponed during the lockdown period. There has been an increase in lung cancer treatments.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Covered

By Component, Type, Technique, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo Corporation (Japan), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc. (U.S.), and ALA Scientific Instruments, Inc. (U.S.



Gloabal Perfusion Systems Market Analysis By Component

The oxygenators segment had the largest share of the global perfusion systems market in 2022. The oxygenator can enhance the exchange of oxygen and carbon dioxide in the blood during surgical procedures, especially for a patient who might require interrupting blood flow to a large blood vessel, a critical organ, or the body by removing carbon dioxide from it and adding oxygen. In addition, the increasing incidence of cardiopulmonary failure and the increased number of heart and lung patients propel the market's growth rate.

On the other hand, the heart-lung machines segment is also anticipated to account for a substantial share in the global perfusion systems market owing to a rise in chronic diseases related to cardiovascular, lung, or both. The machine's primary purpose is to oxygenate the body's venous blood supply before pumping it back into the arterial system. Before being returned to the arterial circulation, blood on its way to the heart is diverted through the apparatus. With the aid of a heart-lung machine, the surgeon may safely stop the heart while keeping blood flowing. The device consists of a pump that substitutes for the heart and an oxygenator that serves as the lungs.

Gloabal Perfusion Systems Market Analysis By Type

The bioreactor perfusion systems segment was accountable for the largest market share of the perfusion systems market in 2022. The technique known as "bioreactor perfusion" keeps cells alive in a bioreactor while continuously changing the growth medium. Cells are either kept in the bioreactor or are recycled in this continuous culture process. Because there are no cells in the harvested medium, the reactor can produce more output with greater cell yields and less labor. Perfusion is a method that Millets uses in cell culture. While cellular waste and nutrient-depleted media are eliminated, new media restore nutrients and carbon sources. Factors such as increasing demand for biological products, the constant need for product yield, and reducing production costs propel the bioreactor perfusion systems market.

Small-mammal organ perfusion systems are also foreseen to hold a significant market share since the microvascular flaps' vital storage capacities are extendable through temporary means. Also, the small animal perfusion model helps validate the further study.

Gloabal Perfusion Systems Market Analysis By Technique

The hypothermic machine perfusion systems are accountable for the largest market share over the years. Hypothermic machine perfusion (HMP) improves early graft function in kidney transplantation, through a continuous supply of substrates and waste elimination, especially for marginal organs. In addition, these preservation pumps help preserve organs at temperatures between 1 and 10 degrees Celsius, unlike normothermic preservation using static cold storage for organ preservice. Therefore, the market share is gained from the perfusion systems' advantages, such as long-term graft survival rates, metabolic support, and reduced vasospasm.

The normothermic perfusion machine (NMP) simulates physiological settings, making it easier to evaluate an organ's quality before transplantation objectively. Many transplant hospitals are developing their MPN procedures, and kidney viability standards as MPN is gaining popularity quickly. Organs are frozen in a preservation solution or preserved at their natural physiological temperature.


Geographically, the North American perfusion systems market is anticipated to account for the largest share of the global perfusion systems market during the forecast period. An increasing number of organ transplant surgeries, technological advancements, and healthcare expenditures influence this region's market growth. However, increasing heart and lung patient rates and improving healthcare facilities are anticipated to grow the market.

The perfusion systems market in Europe held a substantial market share in the global market in the recent past owing to the increase in the prevalence of cardiovascular diseases and rising respiratory diseases. In addition, the growing aging population in this region is propelling the market share. As a result, the market is expected to have better growth during the forecast period.

The Asia Pacific perfusion systems market is forecasted to register the fastest growth rate during the forecast period. Increasing cardiovascular diseases, rising biologics manufacturing activities, the government's and NGOs' initiatives to encourage organ donations, and increasing investments by the government and NGOs to improve healthcare infrastructure create the market share of the perfusion systems market.

The perfusion systems market in Latin America is expected to showcase a steady CAGR during the forecast period

The MEA perfusion systems market is estimated to grow at a healthy CAGR between 2022 to 2027. A growing aging population, government investments, increasing organ donations, and active participation of key market players are anticipated to increase market growth during the market forecast period.


Some of the major companies operating in the global perfusion systems market profiled in the report are Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo Corporation (Japan), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc. (U.S.) and ALA Scientific Instruments, Inc. (U.S.).


  • In October 2022, Universitaire Ziekenhuizen and AZ Universitair Ziekenhuis, to increase the survivability of a donated organ during the critical time between donation and transplantation, surgeons performed the first kidney transplant surgeries using the LifePort Kidney Transporter.

  • In August 2022, doctors transplanted 129,681 organs 2020, according to the Global Donation and Transplantation Observatory. The infusion device OrganEx passes a specially designed fluid and promotes cellular health throughout the body of the pig animal, similar to a cardiopulmonary bypass.

  • In November 2022, advances improved using artificial intelligence (AI), like diagnostic accuracy of coronary heart disease and the prediction of patient risk, led by Piotr Slomka and a researcher in the Division of Artificial Intelligence for the facilitation of one of the most common deadly heart conditions.
  • In July 2019, India Medtronic Private Limited, a wholly-owned subsidiary of Medtronic plc., announced the launch of the vena seal closure system, which is a minimally invasive procedure system that uses proprietary medical adhesive to close to the diseased vein in patients with the chronic venous disease (CVD).
  • In January 2019, Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, announced the launch of its smallest full-size adult oxygenator, the Capiox, NX19 Oxygenator with Ultra prime technology. 


This market research report on the global perfusion systems market has been segmented and sub-segmented into the following categories.

By Component

  • Heart-lung Machines
  • Perfusion Pumps
  • Oxygenators
  • Monitoring Systems
  • Cannulas

By Type

  • Bioreactor Perfusion Systems
  • Microfluidic Perfusion Systems
  • Gravity/Pressure-driven Perfusion Systems
  • Small-mammal Organ Perfusion Systems

By Technique

  • Hypothermic Machine Perfusion Systems
  • Normothermic Machine Perfusion Systems

 By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

Does this report include the impact of COVID-19 on the perfusion systems market?

Yes, we have studied and included the COVID-19 impact on the global perfusion systems market in this report. 

Which region will lead the perfusion systems market in the future?

Geographically, the North American regional market dominated the perfusion systems market in 2023. 

At What CAGR, the global perfusion systems market is expected to grow from 2024 to 2029?

The global perfusion systems market is estimated to grow at a CAGR of 3.4% from 2024 to 2029. 

How much is the global perfusion systems market going to be worth by 2029?

As per our research report, the global perfusion systems market size is projected to be USD 1.42 billion by 2029. 

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample